Comparison of Two Different Doses of Bemiparin in COVID-19

Ensayo clínico Aleatorizado, Abierto, Para Evaluar el Efecto de Dosis profilácticas o terapéuticas de Bemiparina en Pacientes Con COVID-19

Patients requiring hospitalization due to COVID-19 pneumonia (non-severe) will be randomized to standard prophylactic doses or full therapeutic dose of bemiparin (a LMWH) for 10 days.

Inclusion Criteria:

• Age (equal or more than 18 yo)
• Hospitalization at conventional wards due to COVID-19 related mild or moderate pneumonia (CURB65<3 points; Sat. O2>90%)
• 3-4 points according to the WHO ordinal scale.
• Confirmed COVID-19 (PCR or other validated test)
• D-dimer >500 ng/mL
• Sign of informed consent
• The patient is able, according to investigator's opinion, to deal with all the requirements of the clinical trial.

Exclusion Criteria: